[{"orgOrder":0,"company":"Alteogen","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Antibody-drug Conjugate","year":"2024","type":"Licensing Agreement","leadProduct":"Trastuzumab Deruxtecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Preclinical","graph3":"Alteogen","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alteogen \/ Daiichi Sankyo","highestDevelopmentStatusID":"4","companyTruncated":"Alteogen \/ Daiichi Sankyo"},{"orgOrder":0,"company":"Hyundai ADM Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Cytotoxic Drug","year":"2025","type":"Inapplicable","leadProduct":"Docetaxel","moa":"Tubulin","graph1":"Oncology","graph2":"Preclinical","graph3":"Hyundai ADM Bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Hyundai ADM Bio \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Hyundai ADM Bio \/ Inapplicable"},{"orgOrder":0,"company":"Hyundai Bioscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Docetaxel","moa":"Tubulin","graph1":"Oncology","graph2":"Preclinical","graph3":"Hyundai Bioscience","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hyundai Bioscience \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Hyundai Bioscience \/ Inapplicable"},{"orgOrder":0,"company":"Genuv","sponsor":"Nanocarry Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Antibody","year":"2022","type":"Collaboration","leadProduct":"GNUV201","moa":"PD-1","graph1":"Oncology","graph2":"Preclinical","graph3":"Genuv","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Genuv \/ Nanocarry Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Genuv \/ Nanocarry Therapeutics"},{"orgOrder":0,"company":"Voronoi","sponsor":"ORIC Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2020","type":"Licensing Agreement","leadProduct":"ORIC-114","moa":"EGFR","graph1":"Oncology","graph2":"Preclinical","graph3":"Voronoi","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Voronoi \/ ORIC Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Voronoi \/ ORIC Pharmaceuticals"},{"orgOrder":0,"company":"Bridge Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"BBT-207","moa":"EGFR","graph1":"Oncology","graph2":"Preclinical","graph3":"Bridge Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bridge Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Bridge Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Wellmarker Bio","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Antibody","year":"2023","type":"Collaboration","leadProduct":"Pembrolizumab","moa":"||Checkpoint protein","graph1":"Oncology","graph2":"Preclinical","graph3":"Wellmarker Bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Wellmarker Bio \/ Merck & Co","highestDevelopmentStatusID":"4","companyTruncated":"Wellmarker Bio \/ Merck & Co"},{"orgOrder":0,"company":"iNtRON Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"P18-BE3CRC","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"iNtRON Biotechnology","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"iNtRON Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"iNtRON Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"D&D Pharmatech","sponsor":"Yale University","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2021","type":"Agreement","leadProduct":"Undisclosed","moa":"||VEGF-C receptor","graph1":"Oncology","graph2":"Preclinical","graph3":"D&D Pharmatech","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"D&D Pharmatech \/ Yale University","highestDevelopmentStatusID":"4","companyTruncated":"D&D Pharmatech \/ Yale University"},{"orgOrder":0,"company":"LegoChem Biosciences","sponsor":"CStone Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Antibody-drug Conjugate","year":"2020","type":"Licensing Agreement","leadProduct":"LCB71","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"LegoChem Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"LegoChem Biosciences \/ CStone Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"LegoChem Biosciences \/ CStone Pharmaceuticals"},{"orgOrder":0,"company":"J Ints Bio","sponsor":"Yuhan Corporation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"JIN-A04","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"J Ints Bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"J Ints Bio \/ Yuhan Corporation","highestDevelopmentStatusID":"4","companyTruncated":"J Ints Bio \/ Yuhan Corporation"},{"orgOrder":0,"company":"Bridge Biotherapeutics","sponsor":"Emory University","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2024","type":"Collaboration","leadProduct":"BBT-877","moa":"||Autotaxin","graph1":"Oncology","graph2":"Preclinical","graph3":"Bridge Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Bridge Biotherapeutics \/ Emory University","highestDevelopmentStatusID":"4","companyTruncated":"Bridge Biotherapeutics \/ Emory University"},{"orgOrder":0,"company":"Kainos Medicine","sponsor":"Emmaus Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"KM10544","moa":"IRAK4","graph1":"Oncology","graph2":"Preclinical","graph3":"Kainos Medicine","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kainos Medicine \/ Emmaus Life Sciences","highestDevelopmentStatusID":"4","companyTruncated":"Kainos Medicine \/ Emmaus Life Sciences"},{"orgOrder":0,"company":"LegoChem Biosciences","sponsor":"Iksuda","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Antibody-drug Conjugate","year":"2020","type":"Licensing Agreement","leadProduct":"LCB73","moa":"CD19","graph1":"Oncology","graph2":"Preclinical","graph3":"LegoChem Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"LegoChem Biosciences \/ Iksuda","highestDevelopmentStatusID":"4","companyTruncated":"LegoChem Biosciences \/ Iksuda"},{"orgOrder":0,"company":"CanariaBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"MAb-AR20.5","moa":"MUC1","graph1":"Oncology","graph2":"Preclinical","graph3":"CanariaBio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CanariaBio \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"CanariaBio \/ Inapplicable"},{"orgOrder":0,"company":"NKMax","sponsor":"Affimed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Antibody","year":"2020","type":"Collaboration","leadProduct":"AFM24","moa":"||EGFR\/CD16A","graph1":"Oncology","graph2":"Preclinical","graph3":"NKMax","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NKMax \/ Affimed","highestDevelopmentStatusID":"4","companyTruncated":"NKMax \/ Affimed"},{"orgOrder":0,"company":"Oncocross","sponsor":"JW Pharmaceutical Corporation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2024","type":"Expanded Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Oncocross","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Oncocross \/ JW Pharmaceutical Corporation","highestDevelopmentStatusID":"4","companyTruncated":"Oncocross \/ JW Pharmaceutical Corporation"},{"orgOrder":0,"company":"Bridge Biotherapeutics","sponsor":"University of Colorado","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2024","type":"Collaboration","leadProduct":"BBT-877","moa":"Autotaxin","graph1":"Oncology","graph2":"Preclinical","graph3":"Bridge Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Bridge Biotherapeutics \/ University of Colorado","highestDevelopmentStatusID":"4","companyTruncated":"Bridge Biotherapeutics \/ University of Colorado"},{"orgOrder":0,"company":"ABL Bio","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Other Large Molecule","year":"2024","type":"Collaboration","leadProduct":"ABL103","moa":"||B7-H4\/4-1BB","graph1":"Oncology","graph2":"Preclinical","graph3":"ABL Bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ABL Bio \/ Merck & Co","highestDevelopmentStatusID":"4","companyTruncated":"ABL Bio \/ Merck & Co"},{"orgOrder":0,"company":"Ligachem Biosciences","sponsor":"Ono Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Other Large Molecule","year":"2024","type":"Licensing Agreement","leadProduct":"LCB97","moa":"L1CAM","graph1":"Oncology","graph2":"Preclinical","graph3":"Ligachem Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ligachem Biosciences \/ Ono Pharmaceutical","highestDevelopmentStatusID":"4","companyTruncated":"Ligachem Biosciences \/ Ono Pharmaceutical"},{"orgOrder":0,"company":"PharmAbcine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"PMC-309","moa":"VISTA","graph1":"Oncology","graph2":"Preclinical","graph3":"PharmAbcine","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PharmAbcine \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"PharmAbcine \/ Inapplicable"},{"orgOrder":0,"company":"PharmAbcine","sponsor":"MSD Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Antibody","year":"2022","type":"Collaboration","leadProduct":"Pembrolizumab","moa":"||VISTA","graph1":"Oncology","graph2":"Preclinical","graph3":"PharmAbcine","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PharmAbcine \/ MSD Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"PharmAbcine \/ MSD Pharmaceuticals"},{"orgOrder":0,"company":"PINOTBIO","sponsor":"Lotte Biologics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Antibody","year":"2023","type":"Financing","leadProduct":"Sacituzumab Govitecan","moa":"Trop2","graph1":"Oncology","graph2":"Preclinical","graph3":"PINOTBIO","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PINOTBIO \/ Lotte Biologics","highestDevelopmentStatusID":"4","companyTruncated":"PINOTBIO \/ Lotte Biologics"},{"orgOrder":0,"company":"Samsung Biologics","sponsor":"BioEleven","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Antibody","year":"2020","type":"Partnership","leadProduct":"BN-101A","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Samsung Biologics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Samsung Biologics \/ BioEleven","highestDevelopmentStatusID":"4","companyTruncated":"Samsung Biologics \/ BioEleven"},{"orgOrder":0,"company":"Samsung Biologics","sponsor":"Kahr Medical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Protein","year":"2021","type":"Agreement","leadProduct":"DSP502","moa":"DSP-Fc","graph1":"Oncology","graph2":"Preclinical","graph3":"Samsung Biologics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Samsung Biologics \/ Kahr Medical","highestDevelopmentStatusID":"4","companyTruncated":"Samsung Biologics \/ Kahr Medical"},{"orgOrder":0,"company":"Samsung Biologics","sponsor":"Kineta","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Antibody","year":"2021","type":"Agreement","leadProduct":"KVA12.1","moa":"VISTA","graph1":"Oncology","graph2":"Preclinical","graph3":"Samsung Biologics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Samsung Biologics \/ Kineta","highestDevelopmentStatusID":"4","companyTruncated":"Samsung Biologics \/ Kineta"},{"orgOrder":0,"company":"Samsung Biologics","sponsor":"LegoChem Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Antibody-drug Conjugate","year":"2024","type":"Partnership","leadProduct":"LCB73","moa":"CD19","graph1":"Oncology","graph2":"Preclinical","graph3":"Samsung Biologics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Samsung Biologics \/ LegoChem Biosciences","highestDevelopmentStatusID":"4","companyTruncated":"Samsung Biologics \/ LegoChem Biosciences"},{"orgOrder":0,"company":"Syntekabio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"STB-C017","moa":"Indoleamine-2,3-dioxygenase","graph1":"Oncology","graph2":"Preclinical","graph3":"Syntekabio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Syntekabio \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Syntekabio \/ Inapplicable"},{"orgOrder":0,"company":"Y-Biologics","sponsor":"3D Medicines Corporation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Antibody","year":"2021","type":"Licensing Agreement","leadProduct":"Envafolimab","moa":"||CD3","graph1":"Oncology","graph2":"Preclinical","graph3":"Y-Biologics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Y-Biologics \/ 3D Medicines Corporation","highestDevelopmentStatusID":"4","companyTruncated":"Y-Biologics \/ 3D Medicines Corporation"},{"orgOrder":0,"company":"GI Innovation","sponsor":"LaNova Medicines","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Protein","year":"2025","type":"Agreement","leadProduct":"GI-102","moa":"||Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"GI Innovation","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"GI Innovation \/ LaNova Medicines","highestDevelopmentStatusID":"4","companyTruncated":"GI Innovation \/ LaNova Medicines"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          IFT FIRST
                          Not Confirmed
                          IFT FIRST
                          Not Confirmed

                          Details : OTX-M is developed from the well-known injectable chemotherapy drug docetaxel, being investigated for the treatment of cancer.

                          Product Name : OTX-M

                          Product Type : Cytotoxic Drug

                          Upfront Cash : Inapplicable

                          January 22, 2025

                          Lead Product(s) : Docetaxel

                          Therapeutic Area : Oncology

                          Highest Development Status : Preclinical

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          IFT FIRST
                          Not Confirmed
                          IFT FIRST
                          Not Confirmed

                          Details : Through this agreement, both companies will conduct clinical trial of GI-102 in combination with LM-302 targeting patients with metastatic pancreatic cancer.

                          Product Name : GI-102

                          Product Type : Protein

                          Upfront Cash : Undisclosed

                          January 22, 2025

                          Lead Product(s) : GI-102,LM-302

                          Therapeutic Area : Oncology

                          Highest Development Status : Preclinical

                          Sponsor : LaNova Medicines

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank

                          03

                          IFT FIRST
                          Not Confirmed
                          IFT FIRST
                          Not Confirmed

                          Details : Daiichi will acquire worldwide rights to use ALT-B4, Alteogen's novel hyaluronidase, to develop and commercialize a subcutaneous version of Enhertu (trastuzumab deruxtecan), a HER2 directed ADC.

                          Product Name : Enhertu

                          Product Type : Antibody-drug Conjugate

                          Upfront Cash : $20.0 million

                          October 11, 2024

                          Lead Product(s) : Trastuzumab Deruxtecan

                          Therapeutic Area : Oncology

                          Highest Development Status : Preclinical

                          Sponsor : Daiichi Sankyo

                          Deal Size : $300.0 million

                          Deal Type : Licensing Agreement

                          blank

                          04

                          IFT FIRST
                          Not Confirmed
                          IFT FIRST
                          Not Confirmed

                          Details : Ono will have an exclusive worldwide right to develop, manufacture and commercialize LCB97, a pre-clinical stage antibody-drug conjugate, for solid tumors.

                          Product Name : LCB97

                          Product Type : Other Large Molecule

                          Upfront Cash : Undisclosed

                          October 10, 2024

                          Lead Product(s) : LCB97

                          Therapeutic Area : Oncology

                          Highest Development Status : Preclinical

                          Sponsor : Ono Pharmaceutical

                          Deal Size : $700.0 million

                          Deal Type : Licensing Agreement

                          blank

                          05

                          IFT FIRST
                          Not Confirmed
                          IFT FIRST
                          Not Confirmed

                          Details : Under the terms, Samsung Biologics will provide antibody development and drug substance manufacturing services as part of LegoChem's ADC program, including LCB73, a CD19-targeted ADC candidate.

                          Product Name : LCB73

                          Product Type : Antibody-drug Conjugate

                          Upfront Cash : Undisclosed

                          July 06, 2024

                          Lead Product(s) : LCB73

                          Therapeutic Area : Oncology

                          Highest Development Status : Preclinical

                          Sponsor : LegoChem Biosciences

                          Deal Size : Undisclosed

                          Deal Type : Partnership

                          blank

                          06

                          IFT FIRST
                          Not Confirmed
                          IFT FIRST
                          Not Confirmed

                          Details : The companies will identify and verify development possibilities for new indications for first-in-class drug pipeline that JW Pharmaceutical is developing in anticancer and regenerative medicine.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Undisclosed

                          May 27, 2024

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Oncology

                          Highest Development Status : Preclinical

                          Sponsor : JW Pharmaceutical Corporation

                          Deal Size : Undisclosed

                          Deal Type : Expanded Collaboration

                          blank

                          07

                          IFT FIRST
                          Not Confirmed
                          IFT FIRST
                          Not Confirmed

                          Details : The collaboration aims to evaluate ABL103 in combination with MSD's anti-PD-1 therapy, Keytruda (pembrolizumab) in patients with advanced or metastatic solid tumors.

                          Product Name : ABL103

                          Product Type : Other Large Molecule

                          Upfront Cash : Undisclosed

                          April 10, 2024

                          Lead Product(s) : ABL103,Pembrolizumab

                          Therapeutic Area : Oncology

                          Highest Development Status : Preclinical

                          Sponsor : Merck & Co

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          08

                          IFT FIRST
                          Not Confirmed
                          IFT FIRST
                          Not Confirmed

                          Details : A collaboration will assess BBT-877, an ATX inhibitor, combined with anti-PD-1 immunotherapy for NSCLC patients with KRAS and P53 mutations resistant to treatment.

                          Product Name : BBT-877

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          March 28, 2024

                          Lead Product(s) : BBT-877,Undisclosed

                          Therapeutic Area : Oncology

                          Highest Development Status : Preclinical

                          Sponsor : Emory University

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          09

                          IFT FIRST
                          Not Confirmed
                          IFT FIRST
                          Not Confirmed

                          Details : The collaboration focuses on BBT-877, an immuno-oncology cancer treatment, conducting preclinical studies to evaluate its potential in enhancing anti-tumor immunity.

                          Product Name : BBT-877

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          March 26, 2024

                          Lead Product(s) : BBT-877

                          Therapeutic Area : Oncology

                          Highest Development Status : Preclinical

                          Sponsor : University of Colorado

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          10

                          IFT FIRST
                          Not Confirmed
                          IFT FIRST
                          Not Confirmed

                          Details : P18-BE3CRC is a drug candidate developed using the Phageria platform technology for bacteriophage-based drugs. It is being evaluated in preclinical trials for the treatment of colorectal cancer.

                          Product Name : P18-BE3CRC

                          Product Type : Other Large Molecule

                          Upfront Cash : Inapplicable

                          February 14, 2024

                          Lead Product(s) : P18-BE3CRC

                          Therapeutic Area : Oncology

                          Highest Development Status : Preclinical

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank